These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 18626630)

  • 1. Current and prospective pharmacological targets in relation to antimigraine action.
    Mehrotra S; Gupta S; Chan KY; Villalón CM; Centurión D; Saxena PR; MaassenVanDenBrink A
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Oct; 378(4):371-94. PubMed ID: 18626630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Migraine: pathophysiology, pharmacology, treatment and future trends.
    Villalón CM; Centurión D; Valdivia LF; de Vries P; Saxena PR
    Curr Vasc Pharmacol; 2003 Mar; 1(1):71-84. PubMed ID: 15320857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of current and prospective antimigraine drugs on the porcine isolated meningeal artery.
    Mehrotra S; Gupta S; Garrelds IM; Villalón CM; Saxena PR; Bogers AJ; Maassenvandenbrink A
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):163-75. PubMed ID: 17103145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs.
    Ramírez Rosas MB; Labruijere S; Villalón CM; Maassen Vandenbrink A
    Expert Opin Pharmacother; 2013 Aug; 14(12):1599-610. PubMed ID: 23815106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Migraine: current concepts and emerging therapies.
    Arulmozhi DK; Veeranjaneyulu A; Bodhankar SL
    Vascul Pharmacol; 2005 Sep; 43(3):176-87. PubMed ID: 16099727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Side effects associated with current and prospective antimigraine pharmacotherapies.
    González-Hernández A; Marichal-Cancino BA; MaassenVanDenBrink A; Villalón CM
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):25-41. PubMed ID: 29226741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
    Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR
    Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments.
    Villalón CM; VanDenBrink AM
    Mini Rev Med Chem; 2017; 17(11):928-938. PubMed ID: 27465216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Migraine: current therapeutic targets and future avenues.
    Arulmozhi DK; Veeranjaneyulu A; Bodhankar SL
    Curr Vasc Pharmacol; 2006 Apr; 4(2):117-28. PubMed ID: 16611154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimigraine drugs.
    Diener HC; Kaube H; Limmroth V
    J Neurol; 1999 Jul; 246(7):515-9. PubMed ID: 10463349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy.
    De Vries P; Villalón CM; Saxena PR
    Eur J Pharmacol; 1999 Jun; 375(1-3):61-74. PubMed ID: 10443565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy.
    Newman-Tancredi A; Conte C; Chaput C; Verrièle L; Audinot-Bouchez V; Lochon S; Lavielle G; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Jun; 355(6):682-8. PubMed ID: 9205951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological synergy: the next frontier on therapeutic advancement for migraine.
    Blumenfeld A; Gennings C; Cady R
    Headache; 2012 Apr; 52(4):636-47. PubMed ID: 22221151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basic mechanisms of migraine and its acute treatment.
    Edvinsson L; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2012 Dec; 136(3):319-33. PubMed ID: 22939884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors.
    Gupta S; Villalón CM
    Pharmacol Ther; 2010 Oct; 128(1):170-90. PubMed ID: 20655327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical considerations for the treatment of elderly patients with migraine.
    Sarchielli P; Mancini ML; Calabresi P
    Drugs Aging; 2006; 23(6):461-89. PubMed ID: 16872231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is selective 5-HT
    Rubio-Beltrán E; Labastida-Ramírez A; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sumatriptan. An updated review of its use in migraine.
    Perry CM; Markham A
    Drugs; 1998 Jun; 55(6):889-922. PubMed ID: 9617601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute management of migraine: triptans and beyond.
    Diener HC; Limmroth V
    Curr Opin Neurol; 1999 Jun; 12(3):261-7. PubMed ID: 10499171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in pharmacological treatment of migraine.
    Diener HC; Limmroth V
    Expert Opin Investig Drugs; 2001 Oct; 10(10):1831-45. PubMed ID: 11772289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.